Premium
Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivo
Author(s) -
Ley Victoria,
LangladeDemoyen Pierre,
Kourilsky Philippe,
LarssonSciard EvaLotta
Publication year - 1991
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830210350
Subject(s) - ctl* , mastocytoma , cytotoxic t cell , biology , in vivo , transfection , interleukin 4 , interleukin 2 , microbiology and biotechnology , immunology , t lymphocyte , interleukin 12 , immune system , in vitro , cancer research , cell culture , tumor cells , biochemistry , genetics
Abstract We have quantitatively studied the effect of interleukin (IL) 2 on the cytotoxic T lymphocyte (CTL) response to tumor cells in vivo. Mastocytoma P815 was transfected with murine IL 2 cDNA (P815‐IL 2) and injected into syngeneic mice. The anti‐tumor response was analyzed and compared with the response induced by the non‐transfected cells. P815 parental cells are highly tumorigenic, causing death within 20‐30 days. In contrast, IL 2‐transfected cells were totally rejected. Co‐injection of IL 2‐secreting and parental cells resulted in the inhibition of growth of both type of tumors. In addition, the response induced by IL 2‐secreting cells protected the mice against a subsequent challenge with P815. Long‐term memory persisted in treated mice 3 months after tumor rejection. Frequencies of CTL precursors and CTL specific for P815 increased as a result of IL 2 secretion by the target cells. Estimates of CTL frequency at days 8 and 12 after injection were 2 to 3 times higher in mice inoculated with P815‐IL 2 cells, and this correlated with tumor rejection.